Bealach amach 5 an M50, Án Bóthar Thuaidh, Fionnghlas, Baile Átha Cliath 11, D11 XKF3
Guthán: 01 8647100



Primary Care Reimbursement Service Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3

Tel: 01-8647100

Pearse Doherty, T.D. Dáil Éireann, Leinster House, Kildare Street, Dublin 2.

11th July 2024

PQ: 27817/24

To ask the Minister for Health if patients previously diagnosed with type 2 diabetes who are then diagnosed with type 1 diabetes based on blood results qualify for the continuous glucose monitoring reimbursement application system; and if he will make a statement on the matter. -Pearse Doherty

Dear Deputy Doherty,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 27817/24), which you submitted to the Minister for Health for response.

The Health Information and Quality Authority (HIQA) published the rapid Health Technology Assessment of Continuous Glucose Monitoring (CGM) in Adults with Type 1 Diabetes Mellitus on 29th September 2023. The published document can be found at https://www.hiqa.ie/reports-and-publications/health-technology-assessment/rapid-health-technology-assessment-continuous.

A single reimbursement application system for Continuous Glucose Monitoring (CGM) sensors came into effect on 1st December 2023 in view of the findings of the HIQA HTA. Due to the budget impact associated with these products (in the order of €5 million per month), the HSE has established a single reimbursement application system for all CGM sensors on the Reimbursement List. Currently reimbursement support is available for patients with Type 1 Diabetes Mellitus, in line with Circular 033/23.

Reimbursement of CGM at this point in time is for patients with Type I Diabetes Mellitus who have required insulin from the outset.

Reimbursement does not extend to other cohorts such as people with Type 2 Diabetes who require insulin, previously diagnosed Type 2 Diabetes which is now classified as Type 1 Diabetes based on laboratory investigations such as C-peptide measurement or diabetes-specific autoantibodies (evolving Type 1 Diabetes without the typical acute presentation) or

latent autoimmune diabetes of adulthood (LADA) etc. These cohorts were not considered in the HIQA HTA.

Yours sincerely,

Suame Dog 6

Suzanne Doyle

Primary Care Eligibility & Reimbursement Service